Vitiligo
Conditions
Keywords
Vitiligo, Macular depigmentation, Stachytarpheta cayensensis
Brief summary
This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.
Detailed description
To evaluate the efficacy and safety of ACH24 compared to placebo in the treatment of vitiligo.The present study aims to register a new product in the country, the ACH24 for the treatment of vitiligo.
Interventions
DRUGGroup 01
ACH24
DRUGGroup 02
Placebo
Sponsors
Ache Laboratorios Farmaceuticos S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients of both sexes, aged between 18 and 65 years, remaining the feasibility of a legal guardian in accordance with need, able to understand and provide written informed consent and able to allow compliance at the treatment and the requirements of the protocol; * Presence of generalized vitiligo; * Able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines.
Exclusion criteria
* Patients with: * Inflammatory diseases; * Alopecia Areata; * Diabetes Type I; * Asthma; * Collagen disease; * Atopic dermatitis; * Psoriasis; * Autoimmune thyroid disease (self reported). ¬ Thyroid problems (represents 15% of people with vitiligo), exclude only those who need to do treatment with corticosteroid or immunosuppressive. * Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study; * Woman in pregnancy or lactation period; * Known allergic reaction against the phytomedicine as assessed by medical history; * Patient that is taking any prohibited medication (Item 9.3); * Participation in last one year of clinical protocols, unless it can be direct benefit to subject; * Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the subject or interfere with the endpoints of study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Repigmentation of the affected area assessed by VASI (vitiligo area scoring index). | Baseline compared to the end of 18 months of treatment | It is considered successful treatment a repigmentation of greater than or equal to 50% of the affected area assessed by VASI (vitiligo area scoring index). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life questionnaire | Baseline and each 12 weeks of treatment (V0, V3, V6, V9, V12, V15, V18) | Dermatology Life Quality Index (DLQI) |
| Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. | Will be evaluated during whole study, at the baseline and after 18 months of treatment | Collection of safety data throughout the whole study period |
Countries
Brazil
Outcome results
None listed